Performance estimate of drug, e.g. probability of cure Preference estimate, e.g. the added utility of 1% more probability of cure Part-worth utility that is yielded by the performance in (1) for a patient with the preference in (2) Probability distribution of the performance of the drug A performance sample from the performance distribution Probability distribution of the preferences of the patient (population)
A sampled preference representing an individual patient Part-worth utility that corresponds to the samples in steps (5) and (7) Repeating this process a large number of times in a Monte Carlo simulation yields a distribution of the part-worth utility of a drug
Steps (1) through (9) are repeated per treatment for each attribute and the results are summed to obtain the probability distribution of each treatment's utility. 
Integration methodology Case on treatments for HIV

Objectives Conclusion
Quantitative patient preferences are increasingly considered for healthcare policy decisions. The objective of this study is to develop a methodology to combine patient preferences with clinical evidence in a multi-criteria framework that takes into account uncertainty in both preferences and clinical evidence. The methodology is illustrated with a case on antiretroviral treatments.
A probabilistic multi-criteria methodology was developed that explicitly combines patient preferences and clinical evidence. The impact of uncertainty in one or both of these on the treatments'patientweighted utilities can be assessed. Although limited by the small number of attributes and preference sample, the illustrative case suggests the choice of HAART is highly sensitive to patient preferences. 
